Patricia Inácio, PhD, science writer —

Strongbridge Biopharma has finished enrolling patients in its Phase 3 LOGICS clinical trial assessing the safety and effectiveness of Recorlev (levoketoconazole) to treat endogenous Cushing’s syndrome, the company announced. “The completion of enrollment of the Phase 3 LOGICS trial for [Recorlev] represents a significant milestone for Strongbridge and…

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still lacking treatment. And federal incentives to boost treatment development for these rare diseases have primarily focused not on creating new…

Excess glucocorticoid levels in Cushing’s syndrome induces whole-body metabolic changes that are likely mediated by an inter-communication between different organs, a mouse study suggests. The study, “Correlation among body composition and metabolic regulation in a male mouse model of Cushing’s syndrome,” was published in the…

Recordati‘s U.S. marketing rights for Cushing’s disease medications Signifor (pasireotide) and Signifor LAR will be handled by the company’s Recordati Rare Diseases subsidiary. The medications will be marketed through Recordati Rare Diseases’ newly established endocrinology franchise, the company said. During the transfer…

More than 70% of patients have been enrolled in Strongbridge Biopharma’s Phase 3 LOGICS clinical trial assessing the safety and effectiveness of Recorlev (levoketoconazole) for treating endogenous Cushing’s syndrome, the company announced. Strongbridge anticipates announcing top-line results from the study before the end of this year and plans to…

Fat accumulation in muscles caused by Cushing’s syndrome leads to impaired muscle function and worse physical performance long after patients have achieved remission with normal cortisol levels, findings from a new study show. The study, “Thigh muscle fat infiltration is associated with impaired physical performance despite…

Recordati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people with endogenous Cushing’s syndrome, the company announced. The decision follows a European Medicines Agency (EMA) committee recommendation in November to approve Isturisa for that…

On average, people with Cushing’s syndrome wait 34 months before receiving a definite diagnosis, but waiting time largely depends on their specific disease subtype, a review study from Germany reports. Cushing’s disease patients — those with a tumor in the pituitary gland — wait the longest for a…

A Phase 3 trial evaluating Corcept Therapeutics‘ relacorilant in treating the high blood pressure and poorer glucose tolerance in people with endogenous Cushing’s syndrome has begun dosing patients in Europe, the company announced. The GRACE trial (NCT03697109) will be conducted at 62 sites in the United States,…

A European Medicines Agency (EMA) committee has recommended the approval of osilodrostat — to be marketed as Isturisa — for the treatment of adults with Cushing’s syndrome. Osilodrostat, formerly known as LCI699, is an oral treatment that inhibits an enzyme called 11-beta-hydroxylase, which is involved in…